399 related articles for article (PubMed ID: 22258721)
1. The glomerular basement membrane as a model system to study the bioactivity of heparan sulfate glycosaminoglycans.
McCarthy KJ; Wassenhove-McCarthy DJ
Microsc Microanal; 2012 Feb; 18(1):3-21. PubMed ID: 22258721
[TBL] [Abstract][Full Text] [Related]
2. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria.
van den Hoven MJ; Wijnhoven TJ; Li JP; Zcharia E; Dijkman HB; Wismans RG; Rops AL; Lensen JF; van den Heuvel LP; van Kuppevelt TH; Vlodavsky I; Berden JH; van der Vlag J
Kidney Int; 2008 Feb; 73(3):278-87. PubMed ID: 18046314
[TBL] [Abstract][Full Text] [Related]
3. The role of heparan sulfate in the glomerular basement membrane.
Morita H; Yoshimura A; Kimata K
Kidney Int; 2008 Feb; 73(3):247-8. PubMed ID: 18195692
[TBL] [Abstract][Full Text] [Related]
4. Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation.
Borza DB
Matrix Biol; 2017 Jan; 57-58():299-310. PubMed ID: 27609404
[TBL] [Abstract][Full Text] [Related]
5. Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria.
Chen S; Wassenhove-McCarthy DJ; Yamaguchi Y; Holzman LB; van Kuppevelt TH; Jenniskens GJ; Wijnhoven TJ; Woods AC; McCarthy KJ
Kidney Int; 2008 Aug; 74(3):289-99. PubMed ID: 18480751
[TBL] [Abstract][Full Text] [Related]
6. Decreased glomerular basement membrane heparan sulfate proteoglycan in essential hypertension.
Heintz B; Stöcker G; Mrowka C; Rentz U; Melzer H; Stickeler E; Sieberth HG; Greiling H; Haubeck HD
Hypertension; 1995 Mar; 25(3):399-407. PubMed ID: 7875766
[TBL] [Abstract][Full Text] [Related]
7. Heparan sulfate--rich anionic sites in the human glomerular basement membrane. Decreased concentration in congenital nephrotic syndrome.
Vernier RL; Klein DJ; Sisson SP; Mahan JD; Oegema TR; Brown DM
N Engl J Med; 1983 Oct; 309(17):1001-9. PubMed ID: 6225948
[TBL] [Abstract][Full Text] [Related]
8. In vivo degradation of heparan sulfates in the glomerular basement membrane does not result in proteinuria.
Wijnhoven TJ; Lensen JF; Wismans RG; Lamrani M; Monnens LA; Wevers RA; Rops AL; van der Vlag J; Berden JH; van den Heuvel LP; van Kuppevelt TH
J Am Soc Nephrol; 2007 Mar; 18(3):823-32. PubMed ID: 17251387
[TBL] [Abstract][Full Text] [Related]
9. Characterization of heparan sulfate isolated from drug glomerular basement membranes.
Linker A; Hovingh P; Kanwar YS; Farquhar MG
Lab Invest; 1981 Jun; 44(6):560-5. PubMed ID: 6453253
[TBL] [Abstract][Full Text] [Related]
10. Breaking down the barrier: evidence against a role for heparan sulfate in glomerular permselectivity.
Harvey SJ; Miner JH
J Am Soc Nephrol; 2007 Mar; 18(3):672-4. PubMed ID: 17301187
[No Abstract] [Full Text] [Related]
11. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.
van den Born J; van Kraats AA; Bakker MA; Assmann KJ; Dijkman HB; van der Laak JA; Berden JH
Diabetologia; 1995 Oct; 38(10):1169-75. PubMed ID: 8690168
[TBL] [Abstract][Full Text] [Related]
12. Loss of heparan sulfate proteoglycan from glomerular basement membrane of nephrotic rats.
Mynderse LA; Hassell JR; Kleinman HK; Martin GR; Martinez-Hernandez A
Lab Invest; 1983 Mar; 48(3):292-302. PubMed ID: 6219248
[TBL] [Abstract][Full Text] [Related]
13. Retention of glomerular basement membrane-proteoglycans accompanying loss of anionic site staining in experimental diabetes.
Templeton DM
Lab Invest; 1989 Aug; 61(2):202-11. PubMed ID: 2755078
[TBL] [Abstract][Full Text] [Related]
14. Association between heparan sulfate proteoglycan excretion and proteinuria after renal transplantation.
Stefanidis I; Heintz B; Stöcker G; Mrowka C; Sieberth HG; Haubeck HD
J Am Soc Nephrol; 1996 Dec; 7(12):2670-6. PubMed ID: 8989747
[TBL] [Abstract][Full Text] [Related]
15. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate.
van den Born J; van Kraats AA; Bakker MA; Assmann KJ; van den Heuvel LP; Veerkamp JH; Berden JH
Diabetologia; 1995 Feb; 38(2):161-72. PubMed ID: 7713310
[TBL] [Abstract][Full Text] [Related]
16. Effect of puromycin aminonucleoside on HSPG core protein content of glomerular epithelial cells.
Kasinath BS; Singh AK; Kanwar YS; Lewis EJ
Am J Physiol; 1988 Oct; 255(4 Pt 2):F590-6. PubMed ID: 2972214
[TBL] [Abstract][Full Text] [Related]
17. Changes in heparan sulfate correlate with increased glomerular permeability.
Groggel GC; Stevenson J; Hovingh P; Linker A; Border WA
Kidney Int; 1988 Feb; 33(2):517-23. PubMed ID: 2452273
[TBL] [Abstract][Full Text] [Related]
18. Glomerular basement membrane heparan sulfate glycosaminoglycan in aminonucleoside of puromycin nephrosis.
Garin EH; Shirey AJ
Child Nephrol Urol; 1988-1989; 9(3):121-6. PubMed ID: 2978121
[TBL] [Abstract][Full Text] [Related]
19. Development of an enzyme immunoassay specific for a core protein epitope of a novel small basement membrane associated heparan sulphate proteoglycan from human kidney.
Stöcker G; Stickeler E; Switalla S; Fischer DC; Greiling H; Haubeck HD
Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):95-9. PubMed ID: 9056750
[TBL] [Abstract][Full Text] [Related]
20. Removal of heparan sulfate from the glomerular basement membrane blocks protein passage.
Wijnhoven TJ; Lensen JF; Wismans RG; Lefeber DJ; Rops AL; van der Vlag J; Berden JH; van den Heuvel LP; van Kuppevelt TH
J Am Soc Nephrol; 2007 Dec; 18(12):3119-27. PubMed ID: 18003778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
